THE HARVARD BUSINESS School Kraft Precision Medicine Accelerator, a multidisciplinary initiative with aims to advance precision medicine, focuses on four workstreams: Direct to Patient, Data & Analytics, Clinical Trials, as well as Venture and Investment. It was recently announced that under the Direct to Patient workstream, five leading cancer organizations, which include the Multiple Myeloma Research Foundation, LUNGevity Foundation, Metastatic Breast Cancer Alliance, Pancreatic Cancer Action Network, and Prostate Cancer Foundation, have convened to advance precision medicine opportunities across various types of cancers.
The Accelerator and the organizations have begun testing the "Right Track" framework to help patients optimize their treatment journey by connecting them with patient-focused organizations as well as testing the program with the goal of closing knowledge gaps about cancer. ■
